Status:
UNKNOWN
Simplification From Protease Inhibitors to Raltegravir
Lead Sponsor:
Hospital Carlos III, Madrid
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A switch from protease inhibitors (PIs) to raltegravir (RAL) will be effective virologically and immunologically. Moreover, it will be associated with significant improvements in the lipid profile in ...
Eligibility Criteria
Inclusion
- HIV1 sero-positive using standard diagnostic criteria
- Plasma viral HIV-RNA below 50 copies/ml within 180 days prior to randomization
- On therapy with protease inhibitors both ritonavir-boosted or un-boosted for at least 6 months prior to study entry
Exclusion
- Pregnancy or breast feeding
- Prior use of Integrase inhibitors
- Alcohol or substance abuse if according to the investigator opinion would interfere with compliance
- UIse of investigational medications within 30 days before study entry or during the trial
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00941083
Start Date
January 1 2009
End Date
December 1 2009
Last Update
September 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Carlos III
Madrid, Madrid, Spain, 28029